ABANDONED - NO STATEMENT OF USE FILED
no statement of use filed
on 27 Mar 2023
Last Applicant/ Owned by
8480 HONEYCUTT ROAD, SUITE 120
RALEIGH
NC
27615
Serial Number
88573422 filed on 09th Aug 2019
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
NINEMETERS BIOPHARMA
Pharmaceutical and biological preparations for the treatment of anorectal diseases and gastrointestinal and liver disorders; Targeted pharmacological and biological treatments for anorectal diseases, liver, and gastrointestinal disorders such as fecal incontinence, pruritus ani, and radiation proctitis; Prescription and non-prescription pharmacological and biological treatments administered in var Read More
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical and biological preparations for the treatment of anorectal diseases and gastrointestinal and liver disorders; Targeted pharmacological and biological treatments for anorectal diseases, liver, and gastrointestinal disorders such as fecal incontinence, pruritus ani, and radiation proctitis; Prescription and non-prescription pharmacological and biological treatments administered in various pharmaceutical technological forms namely, in solid form pills, tablets, capsules, caplets, sachets, in semi-liquid form namely, gels, ointments and pastes, suppositories, in liquid form namely, drops, injectables, infusions, in gaseous form namely, inhalants, or in sprays, namely, intranasally administered medications, for the treatment of anorectal diseases and gastrointestinal illnesses and disorders; Capsules sold empty for pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Suppositories with proprietary delivery system for the precise delivery of drugs that target conditions and diseases of the anorectal region; Suppositories
Class [042]
Computer & Software Services & Scientific Services
Pharmaceutical research and development services; Medical and scientific research information in the field of novel pharmaceutical discovery and development; Research and development in the pharmaceutical and biotechnology fields; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Medical and scientific research, namely, conducting clinical trials for others of New Therapeutic Entities (NTEs) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither New Chemical Entities (NCEs) nor generics and New Chemical Entities (NCEs) and Biologic License Application (BLAs) as novel pharmaceutical treatments; Research and development in the field of New Therapeutic Entities (NTEs) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither New Chemical Entities (NCEs) nor generics and New Chemical Entities (NCEs) and Biologic License Application (BLAs) as novel pharmaceutical treatments; Research and development in the field of novel pharmaceutical treatments and clinical trials; Providing medical and scientific research information in the field of novel pharmaceutical treatments and clinical trials; Clinical trials services for others
Mark Details
Serial Number
No 88573422
Mark Type
No Service Mark
Attorney Docket Number
No 030525.007
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 27th Mar 2023 | ABANDONMENT - NO USE STATEMENT FILED |
| 27th Mar 2023 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| 13th Aug 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 12th Aug 2022 | SOU EXTENSION 5 GRANTED |
| 12th Aug 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 04th Aug 2022 | SOU EXTENSION 5 FILED |
| 04th Aug 2022 | TEAS EXTENSION RECEIVED |
| 15th Feb 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 11th Feb 2022 | SOU EXTENSION 4 FILED |
| 11th Feb 2022 | TEAS EXTENSION RECEIVED |